Name: AQST Income Statement - Aquestive Therapeutics Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

AQST - Aquestive Therapeutics, Inc.

USD | NASDAQ | Healthcare

AQST Income Statement - Aquestive Therapeutics Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q3 FY 17	Q2 FY 17
Revenues
Revenues	14.4	13.0	12.8	10.0	8.7	11.9	13.5	20.1	12.1	13.2	13.0	13.2	11.1	10.7	11.5	13.3

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Revenues
Revenues	50.3	44.5	57.6	50.6	47.7	50.8	45.8	52.6	67.4	66.9
Cost of Revenue	18.4	18.6	17.9	20.8	19.4	-	13.0	20.4	-	-
Gross Profit	31.9	26.0	39.7	29.8	28.3	-	32.9	32.2	-	-
Operating Expenses
Research & Development	16.0	17.2	20.3	13.1	17.5	17.0	19.9	20.6	23.1	22.1
Selling General & Administrative	71.8	79.8	50.2
Operating Income
Operating Income	(55.9)	(71.1)	(30.8)	(15.1)	(42.1)	(34.7)	(42.9)	(52.7)	(48.9)	(0.1)
Non-Operating
Interest Income	-	-	-	-	-	-	0.1	0.6	-	-
Interest Expense	11.2	11.1	11.1	6.3
Tax & Net
Income Tax Expense	0.0	0.0	(0.0)	0.2	0.0	0.0	0.0	0.0	0.0	0.0
Net Income From Continuing Ops	(68.9)	(83.8)	(44.1)
Per Share
EPS Basic	(0.56)	(0.78)	(0.51)	(0.13)	(1.12)	(1.85)	(1.66)	-	-	-
EPS Diluted	(0.56)	(0.78)	(0.51)	(0.13)
Supplementary Data
EBITDA	(55.4)	(70.5)	(30.1)	(13.8)	(39.7)	(31.7)	(39.5)	(49.8)	(45.7)	3.6
EBIT	(55.9)	(71.1)	(30.8)	(15.1)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Income
Operating Income	(4.2)	(28.8)	(11.5)	(11.4)	(19.4)	(13.6)	(8.3)	0.1	(9.0)	(3.9)	(2.4)	(4.2)	(4.6)	(10.7)	(8.9)	(12.8)	(9.7)	(11.7)	(8.0)	(6.5)	(8.5)	(15.6)	(13.8)	0.4	(13.9)	(9.9)	(11.0)	(18.7)	(13.1)	(12.3)	(9.2)	(32.7)	5.3	10.4	(4.1)

Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	-	-	0.1	0.2	-	-	-	-	-	-	-
Interest Expense	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.3	1.3	1.4	1.4	1.7	1.6	1.6	1.6	1.7
Income From Equity Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pre-Tax Income	(8.1)	(31.9)	(15.4)	(13.5)	(22.9)	(17.1)	(11.5)	(2.7)	(12.8)	(8.0)	(2.2)	(5.5)	8.1	(12.4)	(12.5)	(16.3)

Tax & Net
Income Tax Expense	0.0	0.0	0.0	0.0	0.0	(0.0)	0.0	0.0	0.0	0.1	(0.1)	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income From Continuing Ops	(8.1)	(31.9)	(15.4)	(13.5)	(22.9)	(17.1)	(11.5)	(2.7)	(12.8)	(8.1)	(2.0)	(5.8)	8.1	(12.4)	(12.5)	(16.3)	(13.2)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(8.1)	(31.9)	(15.4)	(13.5)	(22.9)	(17.1)	(11.5)	(2.7)	(12.8)	(8.1)	(2.0)	(5.8)	8.1	(12.4)	(12.5)	(16.3)	(13.2)
Net Income Attributable To Parent	(8.1)	(31.9)	(15.4)	(13.5)	(22.9)	(17.1)	(11.5)	(2.7)	(12.8)	(8.1)	(2.0)	(5.8)	8.1	(12.4)	(12.5)	(16.3)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(8.1)	(31.9)	(15.4)	(13.5)	(22.9)	(17.1)	(11.5)	(2.7)	(12.8)	(8.1)	(2.0)	(5.8)	8.1	(12.4)	(12.5)

Per Share
EPS Basic	(0.07)	-	(0.14)	(0.14)	(0.24)	-	(0.13)	(0.03)	(0.17)	-	(0.03)	(0.10)	0.15	-	(0.23)	(0.36)	(0.32)	-	(0.37)	(0.33)	(0.41)	-	(0.49)	(0.07)	(0.49)	-	(0.74)	(0.82)	-	-	(0.64)	(1.90)	-	-	-
EPS Diluted	(0.07)	-	(0.14)	(0.14)	(0.24)	-	(0.13)	(0.03)	(0.17)	-	(0.03)	(0.10)	0.11	-	(0.23)	(0.36)	(0.32)	-
Shares Basic	122.6	-	110.6	99.3	95.5	-	91.1	90.9	73.6	-	64.7	57.4	55.6	-	53.4	45.5	41.5	-
Shares Diluted	122.6	-	110.6	99.3	95.5	-	91.1	90.9	73.6	-	64.7	57.4	73.8	-	53.4	45.5	41.5	-

Supplementary Data
EBITDA	(4.1)	(28.7)	(11.3)	(11.2)	(19.2)	(13.4)	(8.1)	0.2	(8.8)	(3.4)	(2.2)	(4.0)	(4.3)	(10.3)	(8.3)	(12.1)	(9.0)	(10.9)	(7.2)	(5.8)	(7.8)	(14.5)	(13.1)	1.1	(13.0)	(9.2)	(10.3)	(18.0)	(12.3)	(11.6)	(8.5)	(31.9)	6.2	11.4	(3.1)
EBIT	(4.2)	(28.8)	(11.5)	(11.4)	(19.4)	(13.6)	(8.3)	0.1	(9.0)	(3.9)	(2.4)	(4.2)	(4.6)	(10.7)	(8.9)	(12.8)	(9.7)	(11.7)	(8.0)

Operating Expenses
Research & Development	4.2	3.2	4.5	4.1	5.4	4.9	5.3	4.2	5.9	2.9	3.2	3.5	3.5	4.3	3.2	5.2	4.8	4.4	4.7	4.3	3.7	4.4	7.3	3.8	4.4	3.1	5.1	8.2	4.3	5.7	4.5	8.0	4.9	5.7	4.8
Selling General & Administrative	11.0	32.8	15.3	12.7	19.1	16.0	12.1	11.4	10.7	9.6	7.4	7.4	7.5	11.8	12.5	15.6
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.6	0.2	0.3	0.3	0.4	0.6	0.7
Amortization of Intangibles	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	18.7	41.9	24.3	21.4	28.1	25.4	21.8	20.0	21.0	17.1	15.4	17.5	15.7	21.4	20.3	26.0